Home › Therapeutic areas › Respiratory
Respiratory (27 companies · 9 conditions)
Conditions
Companies
| Ticker | Company | Therapeutic areas | In Respiratory | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 2 | Phase 3 | $608M | 5 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | $536M | 7 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 4 | Phase 2 | — | 9 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 2 | $2.14B | 6 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 1 | Phase 3 | $2.20B | 6 |
| CNTB | Connect Biopharma | Respiratory | 4 | Phase 2 | $37.3M | 4 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $375M | 4 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $858M | 7 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | 1 | Phase 2 | $21.8M | 2 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 7 | Approved | $26.7B | 15 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $10.4B | 5 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 3 | Approved | $5.11B | 9 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | 1 | NDA Submitted | $1.28B | 3 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $47.7M | 8 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.04B | 6 |
| PRME | Prime Medicine | GI/HepatologyRespiratory Rare | 1 | Phase 1 | $699M | 3 |
| RNTX | Rein Therapeutics | Respiratory Rare | 1 | Phase 2 | $30.7M | 1 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 1 | Phase 3 | $4.7M | 11 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 1 | Approved | $1.58B | 11 |
| SION | Sionna Therapeutics | Respiratory Rare | 5 | Phase 2 | $139M | 5 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 1 | Phase 3 | $3.90B | 5 |
| UPB | Upstream Bio | Respiratory | 2 | Phase 2 | $115M | 3 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 3 | $69.4M | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $560M | 5 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | $1.78B | 12 |
No companies match.